Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced that Elisabet de los Pinos, Chief Executive Officer of Aura, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx conference taking place on Tuesday, November 30, 2021 at 2:15 p.m. Eastern Time. A live w
Click here to view original post